The biggest pharma merger and acquisition deals of 2019
The pharmaceutical industry saw some notable mergers and acquisitions in 2019; this article lists the top 10 by transaction size.
List view / Grid view
The pharmaceutical industry saw some notable mergers and acquisitions in 2019; this article lists the top 10 by transaction size.
A Phase I/IIa study has shown that arfolitixorin along with either irinotecan or oxaliplatin could shrink the size of tumours in colorectal cancer patients...
A key drug used to treat colorectal cancer could have more specific application using a test to show which patients would respond best to the treatment...
Watson for Clinical Trial Matching, an AI platform, has shown an increase of 80 percent in enrolment for breast cancer clinical trials, along with reduced screening times for patients...
Researchers find that vitamin D supplements could help to ease painful Irritable Bowel Syndrome symptoms...
Artemisinin, a potent anti-malarial drug, has been widely hailed as a promising alternative cancer treatment...
Mvasi, a biosimilar to the cancer drug Avastin, is approved for certain colorectal, lung, brain, kidney and cervical cancers…
General study identifies targetable pathway that induces immunosuppressive environment in colorectal cancer...
In an analysis of 6 clinical trials with over 12,800 patients, 3 months of chemotherapy was nearly as effective as 6 months and caused fewer side effects...
7 June 2017 | By Niamh Marriott, Junior Editor
Novartis has entered into a research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist...
6 April 2017 | By Niamh Marriott, Junior Editor
BTG has received Class III CE Mark certification for DC Bead LUMI, the first commercially available radiopaque drug-eluting bead...
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
FITs are considered to be accurate because unlike other tests, they use immunochemical detection methods that are specific to human haemoglobin...
4 July 2016 | By Victoria White, Digital Content Producer
XBiotech’s Xilonix is the first monoclonal antibody immunotherapy to specifically target and neutralise interleukin-1 alpha (IL-1α)...
13 May 2016 | By Victoria White, Digital Content Producer
FRESCO is a Phase III pivotal trial of fruquintinib (HMPL-013) in third-line locally advanced or metastatic colorectal cancer (CRC)...
Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that detailed results from the pivotal Phase III VELOUR study evaluating ZALTRAP® (aflibercept) Injection for Intravenous Infusion for the treatment of patients with previously treated metastatic colorectal cancer were published in the October 2012 edition of the Journal of Clinical Oncology (JCO).